EP2091969A4 - Polypeptides ayant des proprietes antiinflammatoires accrues et cytotoxiques reduites et procedes associes - Google Patents

Polypeptides ayant des proprietes antiinflammatoires accrues et cytotoxiques reduites et procedes associes

Info

Publication number
EP2091969A4
EP2091969A4 EP07812601A EP07812601A EP2091969A4 EP 2091969 A4 EP2091969 A4 EP 2091969A4 EP 07812601 A EP07812601 A EP 07812601A EP 07812601 A EP07812601 A EP 07812601A EP 2091969 A4 EP2091969 A4 EP 2091969A4
Authority
EP
European Patent Office
Prior art keywords
polypeptides
related methods
cytotoxic properties
reduced increased
antiinflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07812601A
Other languages
German (de)
English (en)
Other versions
EP2091969A2 (fr
Inventor
Falk Nimmerjahn
Yoshikatsu Kaneko
Jeffrey V Ravetch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/041791 external-priority patent/WO2007055916A2/fr
Priority claimed from PCT/US2007/008396 external-priority patent/WO2007117505A2/fr
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of EP2091969A2 publication Critical patent/EP2091969A2/fr
Publication of EP2091969A4 publication Critical patent/EP2091969A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP07812601A 2006-10-27 2007-07-03 Polypeptides ayant des proprietes antiinflammatoires accrues et cytotoxiques reduites et procedes associes Ceased EP2091969A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2006/041791 WO2007055916A2 (fr) 2005-11-07 2006-10-27 Reactifs, procedes et systemes pour la selection d'un anticorps cytotoxique ou d'une variante
PCT/US2007/008396 WO2007117505A2 (fr) 2006-04-05 2007-04-03 Polypeptides presentant des proprietes anti-inflammatoires accrues et des proprietes cytotoxiques reduites, et procedes coorespondants
PCT/US2007/072771 WO2008057634A2 (fr) 2006-10-26 2007-07-03 Polypeptides ayant des propriétés antiinflammatoires accrues et cytotoxiques réduites et procédés associés

Publications (2)

Publication Number Publication Date
EP2091969A2 EP2091969A2 (fr) 2009-08-26
EP2091969A4 true EP2091969A4 (fr) 2010-05-12

Family

ID=39367532

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07812601A Ceased EP2091969A4 (fr) 2006-10-27 2007-07-03 Polypeptides ayant des proprietes antiinflammatoires accrues et cytotoxiques reduites et procedes associes

Country Status (3)

Country Link
EP (1) EP2091969A4 (fr)
AU (1) AU2007317755A1 (fr)
WO (1) WO2008057634A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
NZ572379A (en) 2006-04-05 2012-06-29 Univ Rockefeller Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20110039311A1 (en) 2008-03-27 2011-02-17 Novozymes A/S Process for producing fermentation product from lignocellulose-containing material
EA201001678A1 (ru) 2008-04-22 2011-06-30 Те Рокфеллер Юниверсити Способы идентификации противовоспалительных соединений
EP2233499A1 (fr) 2009-03-26 2010-09-29 CSL Behring AG Composition d'anticorps avec Fab sialylation altérée
EP2233502A1 (fr) * 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Anticorps spécifiques à l'antigène syalilé pour le traitement ou prophylaxie des réactions immunitaires inflammatoires non désirables et leurs procédés de production
ES2615881T3 (es) 2009-05-07 2017-06-08 Stallergenes Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa.
SG177764A1 (en) 2009-07-30 2012-03-29 Hoffmann La Roche Enzymatic antibody processing
US20130058917A1 (en) 2010-05-07 2013-03-07 Fabian Käsermann Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column
WO2012012590A2 (fr) 2010-07-23 2012-01-26 Novozymes A/S Procédés pour produire des produits de fermentation
PE20131411A1 (es) 2010-10-05 2013-12-16 Hoffmann La Roche Anticuerpos contra la tweak humana y usos de los mismos
WO2012068134A1 (fr) * 2010-11-15 2012-05-24 Biogen Idec Inc. Enrichissement et concentration d'isoformes de produit choisis par liaison surchargée et chromatographie d'élution
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
WO2012162160A1 (fr) 2011-05-20 2012-11-29 Momenta Pharmaceuticals, Inc. Glycoprotéines modifiées
ES2548215T3 (es) 2011-10-05 2015-10-14 F. Hoffmann-La Roche Ag Proceso para la producción de anticuerpos de la glicoforma G1
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9663581B2 (en) 2012-04-25 2017-05-30 Momenta Pharmaceuticals, Inc. Modified glycoproteins
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US20150252108A1 (en) * 2012-09-26 2015-09-10 Momenta Pharmaceuticals, Inc. Glycoprotein preparations
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
WO2015051293A2 (fr) 2013-10-04 2015-04-09 Abbvie, Inc. Utilisation d'ions métalliques pour moduler les profils de glycosylation des protéines dans le cas de protéines recombinées
WO2015057622A1 (fr) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AU2018388791B2 (en) 2017-12-19 2025-04-03 The Rockefeller University Human IgG Fc domain variants with improved effector function

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039488A1 (fr) * 1995-06-06 1996-12-12 Genentech, Inc. Procede de regulation de la sialylation de proteines produites par une culture de cellules de mammiferes
WO2000063403A2 (fr) * 1999-04-15 2000-10-26 Crucell Holland B.V. Production de proteine de recombinaison dans une cellule humaine
WO2004058944A2 (fr) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Amelioration de la qualite d'un produit dans des procedes de culture de cellules mammiferes en vue de produire des proteines
WO2005063808A1 (fr) * 2003-12-31 2005-07-14 Merck Patent Gmbh Proteine hybride fc-erythropoietine a pharmacocinetique amelioree
WO2007005786A2 (fr) * 2005-06-30 2007-01-11 Centocor, Inc. Procedes et compositions a effet therapeutique ameliore

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039488A1 (fr) * 1995-06-06 1996-12-12 Genentech, Inc. Procede de regulation de la sialylation de proteines produites par une culture de cellules de mammiferes
WO2000063403A2 (fr) * 1999-04-15 2000-10-26 Crucell Holland B.V. Production de proteine de recombinaison dans une cellule humaine
WO2004058944A2 (fr) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Amelioration de la qualite d'un produit dans des procedes de culture de cellules mammiferes en vue de produire des proteines
WO2005063808A1 (fr) * 2003-12-31 2005-07-14 Merck Patent Gmbh Proteine hybride fc-erythropoietine a pharmacocinetique amelioree
WO2007005786A2 (fr) * 2005-06-30 2007-01-11 Centocor, Inc. Procedes et compositions a effet therapeutique ameliore

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DALZIEL MARTIN ET AL: "Lectin analysis of human immunoglobulin G N-glycan sialylation", GLYCOCONJUGATE JOURNAL, vol. 16, no. 12, December 1999 (1999-12-01), pages 801 - 807, XP002575135, ISSN: 0282-0080 *
JASSAL R ET AL: "Sialylation of human IgG-Fc carbohydrate by transfected rat alpha2,6-sialyltransferase.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 17 AUG 2001, vol. 286, no. 2, 17 August 2001 (2001-08-17), pages 243 - 249, XP002574380, ISSN: 0006-291X *
KANEKO Y ET AL: "ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670 - 673, XP008076047, ISSN: 0036-8075 *
KANEKO Y ET AL: "ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670 - 673, XP008076047, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1129594 *
NIMMERJAHN FALK ET AL: "The antiinflammatory activity of IgG: the intravenous IgG paradox", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 204, no. 1, January 2007 (2007-01-01), pages 11 - 15, XP002575137, ISSN: 0022-1007 *
RAJU T SHANTHA ET AL: "Glycoengineering of therapeutic glycoproteins: In vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 40, no. 30, 31 July 2001 (2001-07-31), pages 8868 - 8876, XP002461128, ISSN: 0006-2960 *
SCALLON ET AL: "Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 7, November 2006 (2006-11-01), pages 1524 - 1534, XP005792683, ISSN: 0161-5890 *
See also references of WO2008057634A2 *
WANG W-C ET AL: "THE IMMOBILIZED LEUKOAGGLUTININ FROM THE SEEDS OF MAACKIA-AMURENSIS BINDS WITH HIGH AFFINITY TO COMPLEX-TYPE ASN-LINKED OLIGOSACCHARIDES CONTAINING TERMINAL SIALIC ACID-LINKED .ALPHA.-2 3 TO PENULTIMATE GALACTOSE RESIDUES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 263, no. 10, 5 April 1988 (1988-04-05), pages 4576 - 4585, XP002575136, ISSN: 0021-9258 *
WANG W-C ET AL: "THE IMMOBILIZED LEUKOAGGLUTININ FROM THE SEEDS OF MAACKIA-AMURENSIS BINDS WITH HIGH AFFINITY TO COMPLEX-TYPE ASN-LINKED OLIGOSACCHARIDES CONTAINING TERMINAL SIALIC ACID-LINKED ALPHA-2 3 TO PENULTIMATE GALACTOSE RESIDUES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 10, 1988, pages 4576 - 4585, XP002575136, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2008057634A3 (fr) 2008-12-04
WO2008057634A2 (fr) 2008-05-15
EP2091969A2 (fr) 2009-08-26
AU2007317755A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
EP2091969A4 (fr) Polypeptides ayant des proprietes antiinflammatoires accrues et cytotoxiques reduites et procedes associes
BRPI0719369A2 (pt) Porta-prótese e aplicações do mesmo
GB2446843B (en) Amplifier circuit and methods of operation thereof
EP1967207A4 (fr) Inhibiteur de l'induction des cellules t cytotoxiques
DK3207941T6 (da) Fremgangsmåder og sammensætninger baseret på diphtheritoksin-interleukin-3-konjugater
EP1987184A4 (fr) Pièces carbone/carbone et procédés pour les fabriquer
EP2007877A4 (fr) Procedes d'agregation compacte de cellules dermiques
DK2865361T3 (da) Tåreimplantater og tilhørende fremgangsmåder
EP2197380A4 (fr) Instrument et procédé électro-chirurgical
GB0904193D0 (en) Powered wheelchair having an articulating beam and related methods of use
DK2069312T3 (da) Pyridazinonderivater
DK3263589T3 (da) Peptidesekvenser og sammensætninger
ZA200806288B (en) Rage fusion proteins and methods of use
TWI349426B (en) Bias circuit and power amplifier
EP1972256A4 (fr) Endoscope et endoscope rotatif auto-moteur
EP1991565A4 (fr) Protéines chimériques du toxoïde de shiga
IL197543A0 (en) Molecular switches and methods for their use
DE602007006573D1 (de) Magnetische Teilchen und Herstellungsverfahren dafür
EP2066174A4 (fr) Compositions contenant de l'alpha-1-antitrypsine et leurs procédés d'utilisation
ATE537183T1 (de) Hiv-fusionshemmerpeptide mit verbesserten biologischen eigenschaften
DK2099304T3 (da) Carboranylporfyriner og anvendelser deraf
EP1951050A4 (fr) Compositions therapeutiques et procedes
DK2023668T3 (da) Høreapparat med visualiserede psykoakustiske variable og tilsvarende fremgangsmåde
DK2170877T5 (da) Substituerede (oxazolidinon-5-yl-methyl)-2-thiophen-carboxamider og anvendelsen heraf på området for koagulering
DK1937332T3 (da) Infusionsapparat og aktuator hertil

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090519

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RAVETCH, JEFFREY V.

Inventor name: NIMMERJAHN, FALK

Inventor name: KANEKO, YOSHIKATSU

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE ROCKEFELLER UNIVERSITY

A4 Supplementary search report drawn up and despatched

Effective date: 20100414

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135408

Country of ref document: HK

17Q First examination report despatched

Effective date: 20100719

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20130201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1135408

Country of ref document: HK